Inakalant

DB20424InvestigationalSmall molecule

Inakalant is a small molecule drug. The usage of the INN stem '-kalant' in the name indicates that Inakalant is a potassium channel blocker. Inakalant is under investigation in clinical... Inakalant is under investigation in clinical trial NCT00255281 (Efficacy and Safety of AZD7009 in the Treatment of Atrial Fibrillation).

Mechanism: Pharmacologically active on Voltage-gated inwardly rectifying potassium channel KCNH2, Sodium channel protein type 5 subunit alpha, and A-type voltage-gated potassium channel KCND3
Curator reviewed
Formula / weight: C₂₃H₃₄N₄O₅ · 446.548 g/mol (avg)
Code names: AZD-7009

Resolves to

Compound

UNII9GH9N9279TCAS335619-18-6

Structure

InChIKeyJRHUUZPSMQIWBQ-SESVDKBCSA-NSMILESCC(C)(C)OC(=O)NCCN1C[C@H]2CN(C[C@H](O)COC3=CC=C(C=C3)C#N)C[C@@H](C1)O2

Targets

Q12809KCNH2Q14524SCN5AQ9UK17KCND3P22460KCNA5P51787KCNQ1

What you can answer from here — as of August 31, 2026

5Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Inakalant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account